Registry to Detect and Prevent Heart Problems Caused by Cancer Treatments in Adults with Cancer
Led by University of Bologna · Updated on 2025-06-19
10000
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying cancer-related cardiovascular toxicity, which includes heart problems caused by chemotherapy drugs and radiotherapy in people with cancer. The goal is to identify ways to predict, prevent, and treat heart damage related to cancer treatments. This observational study aims to better understand these cardiovascular risks in cancer patients to improve care.
Participants include those newly diagnosed with breast cancer receiving anthracycline-based chemotherapy with or without radiotherapy, trastuzumab, or other anticancer drugs. A subgroup will have their risk assessed using the HFA-ICOS risk score. The study involves following patients at baseline, 3 months, and 1 year to monitor heart health and treatment effects.
During the study, participants will attend follow-up visits for assessments, including heart function and survival outcomes. Researchers will track all-cause mortality, cardiovascular mortality, and cancer therapy-related cardiovascular toxicity over about three years. The study collects data to help better understand and manage heart risks linked to cancer treatments.
CONDITIONS
Brief Title
Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
Research Team
E
Edina Cenko
M
Maria Bergami
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Collaborating Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years old or older
Able to give informed consent
Diagnosed with cancer and scheduled for treatment by treating physician
Life expectancy greater than 1 year
For HFA-ICOS risk score validation: Newly diagnosed breast cancer patients undergoing treatment with anthracyclines, with or without radiotherapy, trastuzumab, or other anticancer drugs
You will not qualify if you...
Under 18 years old
Unable to give informed consent
Life expectancy less than 1 year
Advanced-stage cancer not eligible for treatment, indicated for palliative care by treating physician
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Monitoring
Duration - Approximately 3 years
Participants who have been diagnosed with cancer and are scheduled for treatment are observed to assess cancer therapy-related cardiovascular toxicity and mortality outcomes.
Follow-up visits at baseline, 3 months, and 1 year
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Observational Study Comparing 3D and 2D Echocardiography for Early Heart Damage Detection in Patients Receiving Anthracyclines and HER2-Targeted Cancer Therapies
Registry to Detect and Prevent Heart Problems Caused by Cancer Treatments in Adults with Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Alexander R Lyon, Teresa López-Fernández, Liam S Couch...